Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients
NCT ID: NCT01003483
Last Updated: 2021-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
80 participants
INTERVENTIONAL
2008-12-01
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
L-carnitine and Metformin in Obese PCOS Women.
NCT03108963
Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age
NCT03905941
Study to Compare Between Combimed Metformin-letrozole and Ovarian Drilling in Pcos With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome
NCT01693289
Comparing the Effects of Oral Contraceptive Pills Versus Metformin
NCT03229057
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
NCT03151005
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Orlistat
The dose of 120 mg orlistat was taken three times daily and the dose remained constant throughout the study period.
orlistat
Tablet,120mg,three times a day,three months
Metformin
The dose of metformin was increased step - wise, from 500 mg once daily for the first week to 500 mg twice daily for the next week, and to 500 mg three times daily for the remaining study period .
orlistat
Tablet,120mg,three times a day,three months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
orlistat
Tablet,120mg,three times a day,three months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PCOS
Exclusion Criteria
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yazd Medical University
OTHER
Yazd Research & Clinical Center for Infertility
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nasim Tabibnejad
Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abbas Aflatoonian, Professor
Role: PRINCIPAL_INVESTIGATOR
Research and Clinical center for Infertility
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research and Clinical Center for Infertility
Yazd, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
616
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.